{"id":"fe-asp","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Coagulopathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fe-ASP combines asparaginase, an enzyme that catalyzes asparagine depletion (used in acute lymphoblastic leukemia therapy), with iron supplementation. This dual mechanism targets asparagine-dependent leukemic cells while addressing iron deficiency that may occur during intensive chemotherapy. The iron component may reduce anemia-related complications in hematologic malignancies.","oneSentence":"Fe-ASP is an iron-asparaginase conjugate that depletes asparagine while delivering iron supplementation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:39:37.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"}]},"trialDetails":[{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT03679780","phase":"PHASE1","title":"The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction","status":"COMPLETED","sponsor":"The University of Texas at Arlington","startDate":"2018-10-01","conditions":"Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction","enrollment":19},{"nctId":"NCT03524651","phase":"PHASE4","title":"Ferrous Acetyl-Aspartate Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia","status":"COMPLETED","sponsor":"Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.","startDate":"2018-05-02","conditions":"Iron Deficiency Anemia","enrollment":60},{"nctId":"NCT03586245","phase":"NA","title":"Iron Absorption From Iron Enriched Aspergillus Oryzae in Females Using Stable Isotope Methodology","status":"COMPLETED","sponsor":"Iowa State University","startDate":"2016-10-28","conditions":"Iron Absorption","enrollment":35},{"nctId":"NCT03156712","phase":"NA","title":"Iron Absorption From Iron-enriched Aspergillus Oryzae","status":"COMPLETED","sponsor":"Iowa State University","startDate":"2013-05-29","conditions":"Iron-deficiency, Absorption; Iron, Anemia, Iron Deficiency","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Omalin","Microfer placebo"],"phase":"marketed","status":"active","brandName":"Fe-ASP","genericName":"Fe-ASP","companyName":"Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.","companyId":"uni-pharma-kleon-tsetis-pharmaceutical-laboratories-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fe-ASP is an iron-asparaginase conjugate that depletes asparagine while delivering iron supplementation. Used for Acute lymphoblastic leukemia (ALL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}